Table 2.

DMPs in AD PBLs Measured by Bisulfite Pyrosequencing and pTau181 Levels

Gene ID	CpG site coordinates GRCh37/Hg19		p Value	AUC (95% CI)	OR (95% CI)
HOXA3	7	27153577	<0.001a	0.68 (0.60–0.77)	1.70 (1.32–2.20)
NXN	17	800086	<0.001a	0.64 (0.56–0.73)	1.16 (1.06–1.27)
ADAM10	15	59041183	<0.001b	0.64 (0.56–0.72)	0.82 (0.72–0.93)
APOE	19	45411874	<0.01b	0.64 (0.56–0.72)	1.67 (1.23–2.27)
TREML2	6	41159608	<0.01b	0.64 (0.56–0.72)	0.94 (0.91–0.98)
BDNF	11	27743583	<0.01a	0.61 (0.53–0.69)	0.80 (0.68–0.94)
TREM2	6	41129712	<0.01a	0.61 (0.52–0.69)	0.93 (0.87–0.98)
ABCA7	19	1046617	<0.05b	0.60 (0.52–0.69)	0.82 (0.68–0.98)
BDNF	11	27743580	<0.05a	0.60 (0.52–0.69)	0.81 (0.68–0.98)
ID			p Value	AUC (95% CI)	OR (95% CI)
Plasma pTau181			<0.001b	0.82 (0.74–0.89)	3.47 (2.14–5.63)

Abbreviations: AD = Alzheimer disease; AUC = area under the receiver operating characteristic curve; DMP = differentially methylated position; ID = identification; OR = odds ratio; pTau = hyperphosphorylated tau.

The table shows DMPs between patients with AD and controls with AUC >0.6.

^aStudent t test.

^bMann Whitney U test.